80 research outputs found

    Product Technology Imitation Over the Product Diffusion Cycle: Which Companies and Product Innovations do Competitors Imitate More Quickly?

    Get PDF
    We contribute to the imitation literature by shedding light on product imitation dynamics over the market evolution, a hitherto-overlooked level of analysis. First, we introduce product diffusion within a more integrative theory of product imitation. Second, we investigate the time to imitation of a new product technology: our baseline hypothesis is that the time to imitation decreases as the product diffusion in the market increases. Third, we extend our prediction by differentiating by the type of innovator—i.e., the market leader and a member of the same strategic group—and by the type of product technology—i.e., functionality-defining technologies and substitute technologies. We hypothesize that, over the product diffusion cycle, product technologies launched by market leaders are copied more quickly than ones launched by non-market leader firms; product technologies launched by members of a focal firm's own strategic group are copied more quickly than ones launched by outsiders; and substitute technologies are copied more quickly than functionality-defining technologies. We test our hypotheses in the context of the UK mobile phone industry, by exploiting a unique database on twenty-two product innovations introduced by thirteen mobile handset manufacturers between 1997 and 2008. The model estimations provide support for most of our hypotheses

    The digital transformation of search and recombination in the innovation function: tensions and an integrative framework*

    Get PDF
    Search and recombination are important mechanisms in the creativity phase of innovation. Digital transformation and the resulting pervasive digitalization of the innovation function have often been associated with increasing possibilities for search and recombination. In this paper, by systematically integrating the search and recombination literature with the literature on digitalization, we demonstrate that digitalization may engender new idiosyncratic tensions in the organizational antecedents of search and recombination and, by implication, in their likely outcomes. We propose that, depending on the interactions among the idiosyncratic tensions identified herein, knowledge recombination might spur very different outcomes, including knowledge layering, knowledge integration, knowledge grafting, or even no recombination at all (which we label “search for the sake of search”). These outcomes may not always be the initially planned desired outcomes. Finally, we provide implications of our integrative framework pertaining to product development and to organizing for innovation

    Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy.

    Get PDF
    Graves' Orbitopathy (GO) is the most frequent extrathyroidal manifestation of Graves' disease (GD). Its ultimate cause remains unclear, but it is commonly considered an autoimmune disorder due to self recognition of autoantigens constitutively expressed by orbital fibroblasts (OFs), and thyroid epithelial cells. High dose intravenous glucocorticoids (ivGC) are the most commonly used treatment for moderately severe and active GO. However, based on the complex pathogenesis of GO, a number of factors may have a protective and maybe a therapeutic role. The use of other medications improving the effect of GC may increase the overall effectiveness of the therapy and reduce GC doses, thereby limiting side effects. Recently, a possible protective role of 3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors, the so-called statins, and perhaps of lowering cholesterol levels, has been proposed. Thus, statins have been reported to be associated with a reduced frequency of GO in GD patients and in recent cross-sectional and retrospective studies a significant correlation was found between the occurrence of GO and both total and LDL-cholesterol in patients with a GD of relatively recent onset, suggesting a role of cholesterol in the development of GO. Moreover, a correlation was found between the GO clinical activity score and total as well as LDL-cholesterol in untreated GO patients, depending on GO duration, indicating a role of cholesterol on GO activity. Therefore, statin treatment may be beneficial for GO. Here we review this subject, which offers new therapeutic perspectives for patients with GO
    corecore